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Abstract
Background: Type 2 diabetes (T2D) is associated with increased risk of progression
to cirrhosis and hepatocellular carcinoma (HCC) in people with chronic liver dis-
eases, particularly non‐alcoholic fatty liver disease (NAFLD). However, the absolute
risk of progression is low. So, it is crucial to accurately identify patients who would
benefit most from hepatology referral and intensified management. Current risk‐
stratification tools are suboptimal and perform worse in people with diabetes.
Aims: To determine whether the addition of complementary biomarker(s) to current
NAFLD risk‐stratification tools in people with T2D could improve the identification
of people who are at increased risk of developing incident cirrhosis or HCC.
Methods: The Edinburgh Type 2 diabetes Study (ET2DS) is a cohort study of men
and women with T2D (n = 1066, age 60–75 at baseline). Cases of cirrhosis and HCC
were identified over 11 years of follow‐up. Biomarkers were measured at baseline
and year 1 and association with incident disease was assessed using logistic
regression.
Results:Of existing risk‐stratification scores tested, the Fibrosis‐4 (FIB‐4) index and
the AST:platelet ratio index (APRI) performed best in this cohort. Addition of hy-
aluronic acid (cut‐point ≥ 50 μ g/L) to FIB‐4 (cut‐point ≥ 1.3) maintained a false
negative rate of ≤25% and reduced the number of people incorrectly identified as
“high risk” for incident disease by ∼50%.
Conclusions: The addition of hyaluronic acid to FIB‐4 reduced the proportion of
people inappropriately identified as “high risk” for development of cirrhosis/HCC in
a community population of otherwise asymptomatic people with T2D. These find-
ings require a validation in independent cohorts.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, pro-
vided the original work is properly cited.
© 2021 The Authors. Obesity Science & Practice published by World Obesity and The Obesity Society and John Wiley & Sons Ltd.
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1 | INTRODUCTION
Non‐alcoholic fatty liver disease (NAFLD) is recognized as the liver
component of the metabolic syndrome, a cluster of conditions
including abdominal obesity, impaired glucose regulation or diabetes,
hypertension, hypercholesterolemia, and hypertriglyceridemia, which
are associated with increased cardiovascular risk.1 With rising pop-
ulation levels of obesity, prevalence of NAFLD is rising and 25% of
people globally may be affected.2 Type 2 diabetes(T2D) is associated
with a further increased prevalence of NAFLD, the prevalence of
NAFLD steatosis being 40–70%.3–6 Furthermore, people with T2D
have a higher incidence of, and risk of progression to, cirrhosis and
hepatocellular carcinoma (HCC).7–11
In T2D, identifying those at increased risk of developing cirrhosis/
HCC is important to prompt intensified lifestyle interventions,
enhanced monitoring of disease progression, and timely initiation of
surveillance for varices and HCC. Screening for NAFLD in T2D is
advocated in European guidelines (European Association for the Study
of the Liver, European Association for the Study of Diabetes, Euro-
pean Association for the Study of Obesity [EASL‐EASD‐EASO]).12
Liver biopsy is the gold‐standard test for staging NAFLD, with
histological fibrosis the most important factor predictive of disease
progression in meta‐analyses.13,14 However, biopsy is not suitable for
population screening as it is an invasive procedure with a risk of
serious complications. Consequently, interest in the identification of
non‐invasive markers that predict those at risk of disease progres-
sion has increased. Many scores have been developed and validated
in NAFLD, including the Fibrosis‐4 Index (FIB‐4), NAFLD Fibrosis
Score (NFS), aspartate aminotransferase (AST):alanine aminotrans-
ferase (ALT) ratio, AST to Platelet Ratio Index (APRI), and Enhanced
Liver Fibrosis (ELF) test.15–19 While these were initially developed to
identify liver fibrosis at the time of testing, their ability to predict
incident cirrhosis and HCC has also been validated.11,20–23
The performance of these scores varies between research co-
horts.20–24 Typically, study populations have consisted of patients
attending hepatology secondary care services and there is much less
evidence to support their utility in community populations. Further-
more, these scores perform less well in people with T2D, with one
study reporting that, over 4‐year follow‐up, 15% of people with
diabetes with a “low‐risk” FIB‐4 score developed decompensated
cirrhosis, and 17% developed HCC; by contrast, in individuals
without diabetes, no participant with a “low‐risk” score developed
decompensated cirrhosis or HCC.25 This group has reported that the
use of current risk‐stratification tools would have resulted in large
numbers of people who did not develop cirrhosis/HCC over 11 year
follow‐up being classified as “high risk” (41% with FIB‐4), while a
significant proportion (18% with FIB‐4) who did develop cirrhosis/
HCC were classified as “low risk” at baseline.26
This study hypothesized that the addition of a complementary
biomarker(s) could improve the performance of current risk‐
stratification tools for the accurate identification of people with
T2D who are at increased risk of developing cirrhosis or HCC.
2 | MATERIALS AND METHODS
2.1 | The Edinburgh Type 2 Diabetes Study
The Edinburgh Type 2 Diabetes Study (ET2DS) is a community‐based
prospective cohort study of older people with T2D. Full methods
have been described previously.27 Briefly, in 2006/2007, participants
aged 60–74 with T2D were randomly selected (in age and sex bands)
from the Lothian Diabetes Register (a database of almost all people
with T2D living in Lothian, Scotland), and were subsequently found to
be largely representative of this sampling population.28
Invitations to participate were sent to 5454 people, of whom
1066 (20%) attended baseline clinic. All 1066 were invited to re‐
attend a clinical and liver assessment after one and four years, 939
attended the year‐1 clinic (deceased n = 15, unable to contact n = 19,
unable to attend n = 93) and 831 the year‐4 clinic (deceased n = 88,
unsuitable for clinical reasons n = 26, uncontactable n = 23, unable
n = 98). All 1066 participants were followed up for outcomes until
death (320 participants) or end of follow‐up in 2018.
2.2 | Data collection‐baseline biomarker
assessment
Assessments were undertaken at dedicated research clinics at the
Wellcome Trust Clinical Research Facility, Western General Hospital,
Edinburgh, United Kingdom, by specially trained research staff using
standard operating procedures.27 Fasting venous blood samples were
collected at baseline. Glycated hemoglobin (HbA1c), ALT, AST, alka-
line phosphatase (ALP), gamma‐glutamyltransferase (γ GT), albumin,
bilirubin, and platelets were analyzed using a Vitros Fusion chemistry
system (Ortho Clinical Diagnostics) at the Western General Hospital.
C‐reactive protein (CRP) was measured using an immunonephelo-
metric assay; interleukin‐6 (IL‐6) and tumor necrosis factor‐alpha
(TNF α) were measured using ELISA (R&D Systems), Glasgow Royal
Infirmary. Hyaluronic acid was measured using a radiometric assay
(Pharmacia). The Enhanced Liver Fibrosis (ELF) test was measured on
fasting venous blood samples from the year‐1 clinic and analyzed
using the ADVIA Centaur immunoassay system (Siemens Healthcare
Diagnostics Inc.) at the iQur Laboratory.
Participants attending the year‐1 research clinics underwent a
full diagnostic liver screen if serum liver enzymes or abdominal
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ultrasound was abnormal (including Hepatitis B and C serology, liver
autoantibody titers, alpha‐fetoprotein, ferritin), and all completed
standard questions on alcohol consumption (AUDIT‐C question-
naire), medication use, and past medical history. Any participant with
routine liver enzyme tests above the laboratory upper limit of normal
(ALT > 50 U/L, AST > 45 U/L, γ GT > 55 U/L, alkaline phosphatase
(ALP) > 125 U/L), AST: ALT ratio > 1, hyaluronic acid > 100 μ g/L (in
the absence of known joint disease), positive liver autoantibodies,
ferritin > 1000 ng/ml, alpha‐feto protein >6 ng/ml, positive hepatitis
B or C serology, spleen diameter > 13 cm, platelets < 150 � 109/L (in
the absence of known hematological cause), or suspected cirrhosis on
ultrasound was referred for specialist hepatology review.
Fibrosis scores were calculated and cut‐point levels were used as
per published work.
‐ AST to Platelet Ratio Index (APRI) was calculated as [(AST (U/L)/
Upper limit normal)/platelets (�109/L)] � 100.15
‐ AST:ALT ratio was calculated as AST (U/L)/ALT (U/L).19
‐ Fibrosis‐4 index (FIB‐4) was calculated as {[age (years) � AST
(U/L)]/[plt (�109/L) � sqrt ALT (U/L)]}.16,23,29,30
‐ NAFLD Fibrosis Score (NFS) was calculated as 1.675 + (0.037 �
age [years]) + (0.094 � BMI [kg/m2]) + (1.13 � IFG/diabetes [yes =
1, no = 0]) + (0.99� [AST (U/L]/ALT [U/L]) − (0.013 � platelet
count [�109/L]) − (0.66 � albumin (g/dl).17
2.3 | Data collection—identification of liver disease
Possible prevalent liver disease was identified by a self‐completion
questionnaire at baseline with subsequent confirmation if a clinician
diagnosis was recorded in primary or secondary care medical records.
Incident cirrhosis/HCC was identified and confirmed using multiple
data sources, including review of all participants' hospital medical
notes (TrakCare, InterSystems Corp) at 11‐year follow‐up; responses
recorded in patient and GP questionnaires sent at year‐4 and year‐
10 follow‐up; hospital discharge data (diagnosis and death codes)
collated by ISD (Information Services Division, NHS Scotland) and
collected at year‐8 follow‐up. All confirmed cases required clinician
diagnosis in secondary care medical notes. Participants were identi-
fied as having “screen‐detected” cirrhosis/HCC if they were referred
to hepatology following year‐1 or 4 research clinic investigation and
remained under hepatology follow‐up until definitive diagnosis was
made. People with prevalent cirrhosis or HCC at the baseline were
excluded from analysis on incident disease.
2.4 | Data analysis
Data were analyzed with R (R Foundation for Statistical Computing:
https://www.R‐project.org/) using a complete‐case analysis. More
than 5% of data were missing for all variables with the exception of
ELF (n = 681) and ultrasound (n = 933). Logistic regression was used
to identify the strength of association between baseline scores and
biomarkers, and incident cirrhosis/HCC in this cohort. Best per-
forming existing risk scores were chosen as the base models;
assessed on performance using C‐statistic (to assess discrimination),
the Hosmer–Lemeshow test for Logistic Regression (to assess cali-
bration, >0.05 accepted) and Aikaike Information Criterion (AIC) (a
measure of overall model performance). Correlation between FIB‐4
and APRI risk scores was assessed using Pearson correlation
coefficient.
The strength of association of additional baseline variables that
have been previously reported as potentially associated with path-
ogenesis or progression of liver disease was assessed. These were
demographics (sex, deprivation index (SIMD), smoking status and
alcohol intake), duration of T2D and HbA1c, metabolic variables
(BMI, waist–hip ratio, cholesterol), markers of liver function and
injury (ALP, γ GT, bilirubin, albumin and hyaluronic acid) and markers
of inflammation (IL‐6, CRP and TNF ∝). Hyaluronic acid, TNF α, and γ
GT were log‐transformed (natural log) to ensure linearity of
response to the logit. Biomarkers that remained significantly asso-
ciated with outcome after correction for markers in the base models,
age and sex, were assessed individually and in combination when
added to the base models using C‐statistic, AIC and Hosmer–
Lemeshow test. Because of the number of cases of cirrhosis/HCC in
this cohort (n = 43), a maximum of three additional biomarkers were
added.
Due to this cohort's mixed population of screen‐detected and
clinician‐diagnosed outcomes, possibly skewing time‐to‐event data as
those who were screen‐detected were often diagnosed at a pre‐
symptomatic stage, the primary analysis (logistic regression) did not
include a time component. A sensitivity analysis was undertaken
using competing risks regression to assess whether there was a sig-
nificant impact of the competing risk of non‐liver death on final
model performance. The Bayesian Information Criterion (BIC) was
used to assess the model performance for the competing risks
regression. A second sensitivity analysis was undertaken excluding
any participant with definite non‐NAFLD disease.
The impact of adding the biomarkers that best improved the
performance of models by AIC was assessed through calculation of
sensitivity, specificity, positive predictive value (PPV), negative
predictive value (NPV), false positive, and false negative rate. To
undertake this, dichotomous cut‐points needed to be allocated for
values of the base model and for biomarkers used. A complete‐case
analysis was undertaken for model development, with only those
participants with all biomarker information available included
(n = 999, of whom 39 developed cirrhosis/HCC).
2.5 | Ethics
Ethical permission for the study was granted by Lothian Medical
Research Ethics Committee (REC reference: 16/SS/0098). All par-
ticipants gave written informed consent.
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3 | RESULTS
3.1 | Participant characteristics and incident events
Baseline characteristics are detailed in Table 1. Mean age was 67.9
years and 51.3% were male. Mean duration of T2D was 8 years,
HbA1c 7.4% (57 mmol/mol), and BMI 31.4 kg/m2. Participants were
predominantly of Caucasian ethnicity (98.3%) and 7 (0.01%) had
cirrhosis/HCC. During follow‐up, 43 participants were identified
with incident cirrhosis/HCC. Of these, 39 developed cirrhosis, of
whom 58% developed varices, ascites, or encephalopathy. There
were 13 cases of HCC (9 participants developed both cirrhosis and
HCC). The etiology of incident disease was NAFLD (n = 31), mixed
NAFLD and alcohol (n = 6), mixed NAFLD and α‐1 antitrypsin
deficiency (n = 1), alcohol (n = 2), autoimmune (n = 1), or no clear
diagnosis (n = 3).
3.2 | Identification of base risk‐stratification model
The performance of five pre‐selected risk scores in the ET2DS
study population is shown in Table 2. The risk scores that showed
best association between score and outcome (cirrhosis/HCC) by
logistic regression assessment were FIB‐4 (C‐statistic 0.86, AIC
244.5) and APRI (C‐statistic 0.85, AIC 246.5), and these were
chosen as base models to assess any incremental benefit of addi-
tional biomarkers. Correlation between APRI and FIB‐4 scores in
the individuals with and without incident cirrhosis/HCC was high
(Pearson's r > 0.9).
3.3 | Association of individual biomarkers with
incident cirrhosis/HCC
Individual baseline biomarkers, in addition to those already in the
FIB‐4 and APRI risk scores, were assessed for their association with
incident cirrhosis/HCC by odds ratio (OR) (Table 3). SIMD, HbA1c,
BMI, ALP, γ GT, bilirubin, hyaluronic acid, TNF ∝, IL‐6, and CRP were
associated (p < 0.1) in univariable analysis. SIMD, BMI, HbA1c, γ GT,
hyaluronic acid, IL‐6 and CRP remained associated (p < 0.05) after
adjustment for age, sex, and individual factors already in the base
models (AST and platelets in both FIB‐4 and APRI, plus ALT and age
in FIB‐4) (Table 3).
3.4 | Addition of individual biomarkers to base
prediction model
Individual biomarkers were added to the base models, and the as-
sociation with incident cirrhosis/HCC was assessed using logistic
regression (Table 4). Those that improved FIB‐4 model performance
most in terms of AIC were HbA1c (improvement in AIC of base model
from 238.2 to 228.7), hyaluronic acid (209.4), and γ GT (205.5). Hy-
aluronic acid and γ GT addition also showed the greatest increase in
C‐statistic performance (from 0.85 to 0.89 and 0.93, respectively).
For APRI, improvement in AIC was also seen most clearly with
HbA1c from 243.8 to 236.2, hyaluronic acid (211.2), and γ GT (219.1),
though with only modest C‐statistic improvements. When hyaluronic
acid alone was added to APRI, the Hosmer–Lemeshow test was sig-
nificant, indicating poor calibration.
Hyaluronic acid, γ GT, and HbA1c were chosen to fit to mixed
models (Table 4). Regardless of the base model used, the addition
of both hyaluronic acid and γ GT further improved model per-
formance, with AIC decreasing to 184.5 (FIB‐4 as base model) or
192.9 (APRI as base model). The addition of HbA1c to either hy-
aluronic acid, γ GT, or both did not improve AIC or C‐statistic
substantially beyond the improvement gained by hyaluronic acid
and γ GT alone.
A sensitivity analysis was undertaken using a compete risk
regression analysis (non‐liver death as the competing risk), which
supports the finding that the addition of hyaluronic acid and/or γ GT
provides the best improvement in model performance (Table 5).
3.5 | Predictive accuracy of the base models plus
additional biomarkers
The models that performed the best according to AIC and C‐statistic
(base models plus hyaluronic acid, γ GT, HbA1c, or combinations)
were assessed for accuracy in the prediction of incident cirrhosis/
HCC using sensitivity, specificity, PPV, NPV, false positive, and
negative rates. APRI plus hyaluronic acid alone was not assessed
further due to poor calibration. Cut‐points used were as follows: for
FIB‐4 the “high risk” of fibrosis (>2.67), “medium to high risk” of
fibrosis (≥1.3), and the “medium to high risk” adjusted for age (>2)
cut‐point; for APRI, the “medium to high risk” of fibrosis (>0.5) cut‐
point; for hyaluronic acid ≥100 μ g/L (appropriate for identification of
fibrosis) and ≥50 μ g/L; for γ GT, the laboratory cut‐point of >55 U/L,
and >20 U/L; for HbA1c > 7.5. The second lower cut‐points for hy-
aluronic acid and γ GT were chosen arbitrarily, with the aim of
attempting to reduce false negative results.
Hyaluronic acid (cut‐point > 50 μ g/L) plus FIB‐4 (≥1.3) was the
only model with a false negative rate ≤25% (n = 10/40), thus
correctly identifying the majority of those truly at high risk at
baseline (Table 6). FIB‐4 plus hyaluronic acid (cut‐point ≥ 50 μ g/L)
reduced the number of people assessed as ‘high‐risk’ that did not
develop cirrhosis/HCC during follow‐up (i.e., false positive rate) by
46% (399–214). Results were similar using the combined fibrosis
marker as a part of the EASL‐EASD‐EASO algorithm. Using APRI as a
base model, false negative rates were ≥50%.
Two sensitivity analyses were undertaken, one excluding par-
ticipants with definite non‐NAFLD disease and another excluding
participants who developed HCC in a non‐cirrhotic liver. Neither
analysis materially changed the results (Tables 7 and 8).
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4 | DISCUSSION
Serum hyaluronic acid in conjunction with the FIB‐4 risk‐stratifica-
tion score reduced the number of false positive results in this cohort,
without substantially increasing the false negative results, either in
isolation or within the EASL‐EASD‐EASO algorithm. To this team's
knowledge, this is the first study to examine the use of hyaluronic
acid for risk stratification of liver disease in a community population
with T2D.
Addition of hyaluronic acid improved the association of the FIB‐
4 model with incident cirrhosis/HCC. Moreover, when hyaluronic
acid (cut‐point ≥ 50 μ g/L) was added to the FIB‐4 risk‐stratification
tool, the number of people inappropriately classified as “high risk”
was reduced by 46% (n = 399 to n = 214), while increasing those
inappropriately classified as “low risk” from 18% to 25% (n = 7 to
n = 10). APRI performed similarly to FIB‐4 as a base model. Both
have similar component factors and the scores were highly corre-
lated. Therefore, the additive effect of using both markers in com-
bination was not assessed. The addition of hyaluronic acid to APRI
had poor calibration and was not assessed further in isolation. A
“high risk” FIB‐4 plus hyaluronic acid score was associated with a
median time‐to‐diagnosis of cirrhosis/HCC for approximately 3
years, with the majority presenting within 6 years. Due to the often
asymptomatic course of NAFLD, it seems likely that a significant
proportion of these individuals had undiagnosed cirrhosis at the time
of the baseline assessment, while the remainder had at least
advanced fibrosis.
The ET2DS specifically studied liver outcomes in a community
population of otherwise‐asymptomatic individuals with T2D, who did
not necessarily have liver disease. Almost all other studies have
identified outcomes in cohorts recruited from secondary care
hepatology clinics, with established NAFLD diagnoses and likely
TAB L E 1 Baseline characteristics of
the study population
Baseline characteristic ET2DS population (n = 1066)
Age 67.9 (4.2)
Sex (male) 547.0 (51.3)




5 (least deprived) 349 (32.7)
Duration T2DM (years) 8.1 (6.5)
HbA1c (%) 7.4 (1.1)
HbA1c (mmol/mol) 57.0 (12.0)
BMI (kg/m2) 31.4 (5.7)
Smoker (current) 154.0 (14.4)
Alcohol (excess)a 207.0 (19.9)
Note: Values are mean (sd) or n (%).
Abbreviations: BMI, body mass index; HbA1c, glycated hemoglobin; T2DM Type 2 diabetes.
aDefined as females > 14 units/week, males > 21 units/week or patient disclosed history of a current
or prior alcohol problem.











ELF 6.89–17.40 3.20 (2.18–4.84) <0.001 195.2 0.83 <0.001
APRI 0.07–1.76 3.02 (2.37–3.94) <0.001 246.5 0.85 0.10
AST:ALT 0.33–1.67 2.03 (1.61–2.57) <0.001 318.4 0.73 0.03
NFS −5.91–2.98 3.11 (2.21–4.46) <0.001 297.3 0.80 0.001
FIB‐4 0.41–7.82 3.42 (2.60–4.62) <0.001 244.5 0.86 0.16
Note: OR calculated per increase of one standard deviation in marker.
Abbreviations: AIC, Akaike Information Criterion; ALT, alanine aminotransferase; AST, aspartate aminotransferase; APRI, AST:platelet ratio index; CI,
confidence interval; ELF, enhanced liver fibrosis; FIB‐4, Fibrosis‐4 Index; NFS, NAFLD Fibrosis Score; OR, odds ratio.
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advanced pathology. European guidelines recommend screening in
populations like the one represented by the ET2DS cohort, making
this a suitable testbed for assessing the impact of potential popula-
tion screening strategies.12 The ET2DS is a moderate‐sized cohort.
Participants were well‐characterized at baseline to allow accurate
determination of any potential additional baseline risk factors and
were followed up using multiple sources of information to accurately
identify incident disease.





cirrhosis/HCC (n = 43)
Population without












Age 67.9 (4.2) 68.5 (4.7) 67.9 (4.2) 1.17 (0.86–1.60) 0.31 ‐ ‐





125 (11.8) 9 (20.9) 116 (11.4) 3.78 (1.38–10.79) 0.01 0.01 0.01
2 206 (19.5) 8 (18.6) 198 (19.5) 1.97 (0.7–5.69) 0.20 0.03 0.06
3 187 (17.7) 8 (18.6) 179 (17.6) 2.18 (0.77–6.3) 0.14 0.09 0.14
4 193 (18.2) 11 (25.6) 182 (17.9) 2.94 (1.14–8.12) 0.03 0.01 0.02
5 (least
deprived)
348 (32.9) 7 (16.3) 341 (33.6)
Duration T2DM (years) 8.1 (6.5) 9.1 (6.2) 8.0 (6.5) 1.17 (0.87–1.51) 0.27 ‐ ‐
HbA1c (%) 7.4 (1.1) 8.1 (1.5) 7.4 (1.1) 1.53 (1.21–1.90) <0.001 <0.001 <0.001
HbA1c (mmol/mol) 57 (12) 65 (16.4) 57 (12) ‐ ‐ ‐ ‐
BMI (kg/m2) 31.4 (5.7) 33.7 (6.2) 31.3 (5.7) 1.44 (1.09–1.87) 0.008 0.02 0.02
Waist‐hip ratio 0.97 (0.1) 0.98 (0.1) 0.96 (0.1) 1.20 (0.88–1.63) 0.25 ‐ ‐
Smoker (current) 153 (14.4) 8 (18.6) 145 (14.3) 1.37 (0.58–2.87) 0.43 ‐ ‐
Alcohol (excess)b 204 (19.8) 13 (30.2) 191 (18.8) 1.81 (0.9–3.46) 0.08 0.73 0.71
Cholesterol (mmol/L) 4.3 (0.9) 4.2 (0.8) 4.3 (0.9) 0.84 (0.59–1.16) 0.31 ‐ ‐
ALT (U/L) 43.2 (14.3) 53.4 (19.9) 42.8 (13.9) 1.56 (1.26–1.94) <0.001 0.07 ‐
AST (U/L) 31.0 (10.4) 45.9 (15.4) 30.4 (9.7) 2.20 (1.78–2.74) <0.001 ‐ ‐
ALP (U/L) 91.7 (27.3) 106.1 (33.5) 91.1 (26.9) 1.45 (1.15–1.82) 0.001 0.21 0.12
γGT (U/L)b 29.4 (40.3) 96.7 (86.7) 26.7 (34.7) 3.55 (2.66–4.86) <0.001 <0.001 <0.001
Bilirubin (μmol//L) 10.0 (4.7) 11.2 (4.1) 9.9 (4.7) 1.24 (0.94–1.56) 0.09 0.63 0.57
Albumin (g/L) 44.8 (3.3) 44.7 (3.8) 44.8 (3.3) 0.97 (0.71–1.33) 0.86 ‐ ‐
Platelets (109/L) 258.7 (69.3) 201.5 (77.4) 261.1 (68.0) 0.33 (0.22–0.49) <0.001 ‐ ‐
Hyaluronic acid (μg/L)c 56.1 (46.6) 132.2 (85.3) 52.8 (41.3) 5.29 (3.42–8.47) <0.001 <0.001 <0.001
TNF‐∝ (pg/ml)c 1.4 (1.5) 1.6 (0.8) 1.3 (1.5) 1.63 (1.19–2.23) 0.002 0.05 0.08
IL‐6 (pg/ml) 3.9 (3.5) 5.7 (3.9) 3.8 (3.5) 1.38 (1.12–1.66) 0.001 0.01 0.02
CRP (mg/L) 3.9 (6.0) 6.0 (8.3) 3.8 (5.9) 1.26 (1.00–1.52) 0.03 0.03 0.03
Note: Values are mean(sd) or n (%)
Abbreviations: γ GT, gamma‐glutamyltransferase; ALP, alkaline phosphatase; AST, aspartate aminotransferase; ALT, alanine aminotransferase; CRP; C‐
reactive protein; HbA1c, glycated hemoglobin; IL‐6 Interleukin‐6; SIMD, Scottish Index of Multiple Deprivation, T2DM Type 2 diabetes; ; TNF‐ ∝ tumor
necrosis factor‐alpha.
aDefined as females > 14 units/week, males > 21 units/week or patient disclosed history of a current or prior alcohol problem.
bResults for the natural log of these values.
cFor continuous variables, odds ratio represents change in odds for standard deviation change in variable.
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There are limitations to this study. The ET2DS is a single‐center
study, undertaken in people aged 60–75 years, of predominantly
Caucasian origin (98.3%) and care should be taken in extrapolating
results to other populations. While the etiology of incident disease
was almost entirely NAFLD, cirrhosis/HCC of other etiologies was
included. There are known difficulties in determining the exact con-
tributions of different etiologies (or cofactors) in cirrhosis/HCC
development; thus, the investigation of all liver diseases seemed
more relevant in a real‐world setting.31 A sensitivity analysis that
excluded participants who developed definite non‐NAFLD disease
did not materially affect results. Medication exposure data were not
analyzed.
The incidence data may be an underestimate as it is possible that
some asymptomatic participants who developed cirrhosis/HCC dur-
ing follow‐up were not identified, as screening for cirrhosis/HCC at
11‐year follow‐up was not repeated. Alternatively, incidence data
may overestimate the clinical burden as a substantial proportion of
diagnoses were made after hepatology referral following year‐1 and
TAB L E 4 Performance of the
baseline models (FIB‐4 and APRI) with
the addition of complementary
biomarkers
Model C‐statistic Hosmer‐Lemeshow p‐value AIC
Base Model
FIB‐4 0.85 0.35 238.2
Addition of one additional variable
FIB‐4 + HbA1c 0.87 0.43 228.7
FIB‐4 + γ GTa 0.93 0.98 205.5
FIB‐4 + HAa 0.89 0.06 209.4
FIB‐4 + BMI 0.87 0.32 232.9
FIB‐4 + SIMD 0.87 0.79 239.6
FIB‐4 + IL‐6 0.87 0.16 235.0
FIB‐4 + CRP 0.88 0.76 235.9
Mixed models
FIB‐4, Hba1c, γ GTa 0.93 0.86 199.2
FIB‐4, Hba1c, HAa 0.90 0.10 203.5
FIB‐4, γ GTa, HAa 0.93 0.23 184.5
Full model FIB‐4, HbA1c, γ GTa, HAa 0.94 0.71 181.0
Base model
APRI 0.85 0.92 243.8
Addition of one additional variable
APRI + HbA1c 0.86 0.93 236.2
APRI + γ GTa 0.91 0.84 219.1
APRI + HAa 0.88 <0.01 211.2
APRI + BMI 0.86 0.52 238.6
APRI + SIMD 0.87 0.18 242.5
APRI + IL‐6 0.88 0.01 239.5
APRI + CRP 0.87 0.28 241.3
Mixed models
APRI, Hba1c, γ GTa 0.91 0.84 213.6
APRI, Hba1c, HAa 0.89 <0.01 206.3
APRI, γ GTa, HAa 0.92 0.20 192.9
Full model APRI, HbA1c, γ GTa, HAa 0.93 0.14 189.7
Abbreviations: γ GT, gamma glutamyltransferase; AIC, Akaike Information Criterion; CRP, C‐
reactive protein; HA, hyaluronic acid; HbA1c, glycated hemoglobin; IL‐6, Interleukin‐6; SIMD, Scottish
Index of Multiple Deprivation.
aLog‐transformed γ GT/HA variable.
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year‐4 screening investigations. NAFLD cirrhosis can have a silent
natural history and may not manifest clinically for many years. Thus,
some people who may never have developed overt cirrhosis, or may
have died before their disease became clinically apparent may have
been identified. However, 58% of those identified with cirrhosis
developed varices, ascites and/or encephalopathy and 23% devel-
oped HCC, so it is likely that a large majority would have presented
with clinical sequelae during follow‐up.
Those who were diagnosed following screening in year 1 may
have had undiagnosed cirrhosis/HCC at the baseline. However, the
study considered prevalent disease to be only that which was clini-
cally apparent at baseline because the diagnosis of cirrhosis for some
referred post‐screening came many years following that referral
(people were kept under active follow‐up due to high‐risk features
for progression). Additionally, the time to diagnosis for those who
were diagnosed following year‐1 screening and those diagnosed
following routine clinical referral significantly overlapped, suggesting
that stage of disease in the two groups at baseline did not differ
significantly.26
ELF was measured at the year‐1 clinic (all other biomarkers at
baseline), so this analysis used slightly different “baseline” time
points. However, this group has demonstrated previously that there
is no significant difference in model performance using baseline or
year‐1 data; in addition, no participant was identified with incident
disease prior to the year‐1 clinics.26 Hyaluronic acid is known to be
raised in the context of joint, as well as liver disease. As accurate data
on joint disease prevalence for the whole cohort at baseline were not
available, individuals with joint disease were not excluded. However,
as hyaluronic acid was used in conjunction with other markers of liver
fibrosis, isolated elevation of hyaluronic acid due to joint disease
should not have had a material impact on the models.
This group has previously described the performance of current
risk‐stratification models in predicting cirrhosis and HCC in
different cohorts.26 In addition, risk‐stratification scores perform
worse in populations with diabetes than in those without.25
Previous cohort studies have failed to consistently identify
individual non‐invasive biomarkers that are associated NAFLD
progression.13,14 This study demonstrates that using serum
hyaluronic acid in conjunction with the FIB‐4 risk‐stratification
score can reduce the burden of false positive results. Hyaluronic
acid is a glycosaminoglycan found in connective tissue that is almost
exclusively cleared by liver metabolism. Raised levels of hyaluronic
acid are known to be associated with cirrhosis.32 However, few
studies have assessed it as a prognostic marker. In combination with
other biomarkers as part of the ELF risk‐stratification tool, hyal-
uronic acid is associated with fibrosis in NAFLD.18 One study found
a significant association with rising hyaluronic acid and all‐cause
mortality, liver mortality and liver transplant‐free survival.33 Thus,
the present data, finding suggesting its utility in predicting those
who are at “high risk” of developing incident cirrhosis/HCC, is
consistent with published data.
The present findings derive from a single moderately sized
cohort and need validation in other independent cohorts. A change in
FIB‐4 plus hyaluronic acid over time was not examined. Moreover,
there were too few individuals who developed cirrhosis/HCC to
determine reliably if the median time‐to‐diagnosis was more pro-
longed in those with a “low‐risk” score compared to those with a
“high‐risk” score. If the time‐to‐diagnosis was more prolonged in
TAB L E 5 Performance of the baseline models (FIB‐4 and
APRI) with the addition of complementary biomarkers, re‐run
using competing risk regression analysis with non‐liver death as
the competing risk
Model BIC (null = 535.75)
Base Model
FIB‐4 467.17
Addition of one additional variable
FIB‐4 + HbA1c 460.27
FIB‐4 + γ GTa 431.97
FIB‐4 + HAa 445.68
FIB‐4 + BMI 469.52
FIB‐4 + SIMD 470.47
FIB‐4 + IL‐6 469.94
FIB‐4 + CRP 472.90
Mixed models
FIB‐4, HbA1c, γ GTa 433.04
FIB‐4, HbA1c, HAa 444.16
FIB‐4, γ GTa, HAa 418.36
Full model FIB‐4, HbA1c, γ GTa, HAa 420.65
Base model
APRI 458.58
Addition of one additional variable
APRI + HbA1c 457.17
APRI + γ GTa 436.10
APRI + HAa 439.09
APRI + BMI 459.60
APRI + SIMD 462.82
APRI + IL‐6 460.00
APRI + CRP 463.22
Mixed models
APRI, HbA1c, γ GTa 439.63
APRI, HbA1c, HAa 439.80
APRI, γ GTa, HAa 419.49
Full model APRI, HbA1c, γ GTa, HAa 423.29
Abbreviations: γ GT, gamma glutamyltransferase; AIC, Akaike
Information Criterion; CRP, C‐reactive protein; HA, hyaluronic acid;
HbA1c, glycated hemoglobin; IL‐6, Interleukin‐6; SIMD, Scottish Index of
Multiple Deprivation.
alog‐transformed γ GT/HA variable.
8 - GRECIAN ET AL.














FIB‐4 > 2.67 40 (25–57) 98 (97–99) 46 (29–63) 98 (96–98) 19 (2) 24 (60)
FIB‐4 > 2.0 62 (46–77) 92 (90–93) 23 (16–33) 98 (97–99) 82 (8) 15 (37)
FIB‐4 ≥ 1.3 82 (67–93) 59 (56–62) 8 (5–11) 99 (98–100) 399 (41) 7 (18)
As addition of further variables will increase false negative values, only FIB‐4 ≥1.3 was taken forward.
FIB‐4 ≥ 1.3, γ GT > 55 45 (29–62) 95 (94–97) 28 (18–41) 98 (97–99) 46 (5) 22 (55)
FIB‐4 ≥ 1.3, γ GT > 20 72 (56–85) 82 (79–84) 14 (10–20) 99 (98–99) 176 (18) 11 (28)
FIB‐4 ≥ 1.3, HA ≥ 100 62 (46–77) 95 (93–96) 32 (22–44) 98 (97–99) 53 (5) 15 (38)
FIB‐4 ≥ 1.3, HA ≥ 50 75 (59‐87) 78 (75–81) 12 (8–17) 99 (98–99) 214 (22) 10 (25)
FIB4 ≥ 1.3, HbA1c > 7.5 47 (32–64) 88 (85–90) 13 (8–20) 98 (96–99) 122 (12) 21 (53)
FIB‐4 ≥ 1.3, HA ≥ 50, γ GT > 20 65 (48‐79) 90 (88–92) 22 (15–30) 98 (97–99) 94 (10) 14 (35)
FIB4 ≥ 1.3, HA ≥ 50, HbA1c > 7.5 45 (29–62) 93 (91–94) 20 (12–30) 98 (96–99) 72 (7) 22 (55)
FIB4 ≥ 1.3, γ GT > 20, HbA1c > 7.5 40 (25–57) 94 (92–95) 22 (13–33) 97 (96–98) 58 (6) 24 (60)
Fib4 ≥ 1.3, HA ≥ 50, GGT > 20, HbA1c > 7.5 38 (23–54) 97 (95–98) 31 (19–46) 97 (96–98) 33 (3) 25 (63)
APRI > 0.5 53 (36–68) 94 (93–96) 27 (18–38) 98 (97–99) 57 (6) 19 (48)
APRI > 0.5, γ GT > 55 35 (21–52) 98 (97–99) 45 (27–64) 97 (96–98) 17 (2) 26 (65)
APRI > 0.5, γ GT > 20 50 (34–66) 96 (95–97) 36 (24–50) 98 (97–99) 35 (4) 20 (50)
APRI > 0.5, HbA1c > 7.5 33 (19–49) 98 (97–99) 37 (21–55) 97 (96–98) 22 (2) 27 (68)
APRI > 0.5, HA ≥ 50, γ GT > 20 50 (34–66) 98 (96–98) 45 (30–61) 98 (97–99) 24 (2) 20 (50)
APRI > 0.5, HA ≥ 50, HbA1c > 7.5 33 (19–49) 98 (97–99) 45 (26–64) 97 (96–98) 16 (2) 27 (68)
APRI > 0.5, γ GT > 20, HbA1c > 7.5 30 (17–47) 99 (98–99) 50 (29–71) 97 (96–98) 12 (1) 28 (70)
APRI > 0.5, HA ≥ 50, GGT > 20, HbA1c > 7.5 30 (17–47) 99 (98–100) 57 (34–78) 97 (96–98) 9 (1) 28 (70)
EASL guidelines‐ USS steatosis + FIB‐4 ≥ 1.3 OR ALT > 50 OR
AST > 45 OR γ GT > 55
86 (71–95) 60 (57–63) 8 (6–11) 99 (98–100) 346 (40) 5 (14)
EASL (USS) + HA ≥50 81 (64–92) 81 (78–84) 15 (10–21) 99 (98–100) 163 (19) 7 (19)
EASL guidelines‐ FLI positive + FIB‐4 ≥ 1.3 OR ALT > 50 OR
AST > 45 OR γ GT > 55
90 (76–97) 58 (55–61) 8 (6–11) 99 (98–100) 411 (42) 4 (10)
EASL (FLI) + HA ≥50 78 (62–89) 79 (76–81) 13 (9–18) 99 (98–99) 206 (21) 9 (23)
Abbreviations: γ GT, gamma‐glutamyltransferase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; FLI, fatty liver index; HA, hyaluronic
acid; HbA1c, glycated hemoglobin; NPV, negative predictive value; PPV, positive predictive value; sens, sensitivity; spec, specificity; USS, ultrasound
assessed.
TAB L E 7 Predictive ability of models by sensitivity, specificity, PPV, NPV, false positives and false negatives‐final models, participants














FIB‐4 ≥ 1.3 84 (68–94) 59 (56–62) 7 (5–10) 99 (98–100) 399 (41) 6 (16)
FIB‐4 ≥ 1.3, HA ≥ 50 78 (62–90) 78 (75–81) 12 (8–17) 99 (98–100) 214 (22) 8 (22)
EASL guidelines‐ USS steatosis + FIB‐4 ≥ 1.3 OR ALT > 50
OR AST > 45 OR γ GT > 55
89 (75–97) 60 (57–64) 8 (6–11) 99 (98–100) 376 (44) 4 (11)
EASL (USS)+ HA ≥50 78 (62–90) 81 (79–84) 14 (10–19) 99 (98–100) 179 (21) 8 (22)
EASL guidelines‐ FLI positive + FIB‐4 ≥ 1.3 OR ALT > 50
OR AST > 45 OR γ GT > 55
89 (75–97) 58 (55–61) 7 (5–10) 99 (98–100) 413 (43) 4 (10)
EASL (FLI) + HA ≥ 50 78 (62–90) 79 (76–81) 12 (8–17) 99 (98–100) 208 (21) 8 (22)
Abbreviations: γ GT, gamma‐glutamyltransferase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; FLI, fatty liver index; HA, hyaluronic
acid; NPV, negative predictive value; PPV, positive predictive value; sens, sensitivity; spec, specificity; USS, ultrasound assessed.
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those with a “low‐risk” score, repeat assessment at intervals of
several years might successfully identify additional individuals who
would develop cirrhosis/HCC.
In conclusion, the prevalence of both NAFLD and T2D are rising
in association with the rising population prevalence of obesity. T2D is
associated with an increased risk of cirrhosis/HCC.8,9 As a result,
both European and American guidelines advocate a high index of
suspicion for liver disease in T2D, with European guidelines recom-
mending routine screening.12,34 However, current risk‐stratification
tools perform sub‐optimally, especially in diabetes.25,26 This study
shows that using a combination of FIB‐4 and hyaluronic acid for risk‐
stratification can significantly reduce false positive rates without
substantially increasing false negative rates. This makes this combi-
nation a possible candidate for community screening, as it would lead
to identification of a substantial proportion of cases while reducing
stress on health systems from false positive results. These findings
are promising, but require further validation. Furthermore, the false
positive rates for the FIB‐4 and hyaluronic acid combination remain
high and so it is acknowledged that better biomarkers are required
for the identification of people with T2D at risk of developing
cirrhosis/HCC.
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